[HTML] springer.comFull View

[HTML][HTML] Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

M Li, G Bai, Y Cen, Q Xie, J Chen, J Chen… - Journal of Translational …, 2023 - Springer
Abstract Background Advanced prostate cancer (PCa) will develop into castration-resistant
prostate cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC …
被引用次数：5 相关文章

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

M Li, G Bai, Y Cen, Q Xie, J Chen… - Journal of …, 2023 - search.proquest.com
Background Advanced prostate cancer (PCa) will develop into castration-resistant prostate
cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC, CRPC-AR …

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

M Li, G Bai, Y Cen, Q Xie, J Chen… - Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Advanced prostate cancer (PCa) will develop into castration-resistant prostate
cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC, CRPC-AR …

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway.

M Li, G Bai, Y Cen, Q Xie, J Chen, Q Chen… - Journal of …, 2023 - europepmc.org
Background Advanced prostate cancer (PCa) will develop into castration-resistant prostate
cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC, CRPC-AR …
[HTML] nih.gov

[HTML][HTML] Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

M Li, G Bai, Y Cen, Q Xie, J Chen, J Chen… - Journal of …, 2023 - ncbi.nlm.nih.gov
Background Advanced prostate cancer (PCa) will develop into castration-resistant prostate
cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC, CRPC-AR …

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway.

M Li, G Bai, Y Cen, Q Xie, J Chen… - Journal of …, 2023 - search.ebscohost.com
Abstract Background: Advanced prostate cancer (PCa) will develop into castration-resistant
prostate cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC …
[HTML] biomedcentral.com

[HTML][HTML] Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

M Li, G Bai, Y Cen, Q Xie… - Journal of …, 2023 - … -medicine.biomedcentral.com
Advanced prostate cancer (PCa) will develop into castration-resistant prostate cancer
(CRPC) and lead to poor prognosis. As the primary subtype of CRPC, CRPC-AR accounts …

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

M Li, G Bai, Y Cen, Q Xie, X Zhou, J Chen, J Chen… - 2023 - researchsquare.com
Background Advanced prostate cancer (PCa) will develop into castration-resistant prostate
cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC, CRPC-AR …

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway.

M Li, G Bai, Y Cen, Q Xie, J Chen, Q Chen… - Journal of …, 2023 - europepmc.org
Background Advanced prostate cancer (PCa) will develop into castration-resistant prostate
cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC, CRPC-AR …
[PDF] biomedcentral.com

[PDF][PDF] Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway

M Li, G Bai, Y Cen, Q Xie, J Chen, J Chen… - 2023 - … -medicine.biomedcentral.com
Abstract Background Advanced prostate cancer (PCa) will develop into castration-resistant
prostate cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC …